Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

ALLO-316, a CD70-targeting CAR T-cell therapy, has demonstrated activity in patients with previously treated, advanced ccRCC.

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

LOUISVILLE, Ky. -- Minimally invasive ablative therapy for early kidney cancer had an increased risk of local and metastatic ...

Title: Comprehensive biomarker analyses from a Phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic ...

Swedish battery manufacturer Northvolt, once the poster child of Europe’s green industry and battery ... Furthermore, Chinese ...

PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) is set to showcase groundbreaking advancements in its iPSC-derived ...

CHANDIGARH: Punjab Police have arrested two key operatives of gangster-turned-terrorist Arsh Dalla in connection with the ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit attended the 5th RAS Initiative Symposium, hearing about ...

AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the ...

Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, 'off-the-shelf' cancer vaccine, designed to save lives by preventing disease recurrence in first-line ...